On 1 July 2015, the Common Arab guidelines on good vigilance practices became effective. The guidance has been developed by a "Higher Technical Committee for Medicines" established by the health ministers of the Arab countries under the umbrella of the Arab league (including Egypt, Saudi Arabia, UAE, Oman, Qatar, Kuwait, Bahrain and Jordan).

A first draft of the guidelines was adopted in March 2014, a second version was published in December 2014.

The guidelines draw their inspiration from the European Good Vigilance Practice (GVP) modules but take into account social, cultural and economic specificities of the region. To this end, feedback was sought from both regulators and pharmaceutical companies.

The guidelines are seen as a model for best practice in pharmacovigilance and aim to harmonize regulations and practices across the Arab world. However, it should be noted that each of the national competent authorities has the right to adopt additional or different measures for their country.